Journal Article Page
European UrologyVolume 63, issue 6, pages e67-e86, June 2013
Indium-111–labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma
Accepted 13 February 2013, Published online 26 February 2013, pages 1101 - 1106
Improved and more frequent radiologic evaluation has resulted in increased identification of renal masses of unknown origin, which frequently pose a diagnostic dilemma for urologists.
Carbonic anhydrase IX (CAIX) is an antigen ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). The specific and high level of expression in ccRCC makes CAIX an excellent target for imaging ccRCC lesions. We present our experience with immuno–single-photon emission computed tomography (immunoSPECT) imaging with the indium-111 (111In)–labeled anti-CAIX antibody girentuximab in patients presenting with either a primary renal tumor or a history of ccRCC and lesions suspect for metastases during follow-up.
Design, setting, and participants
Twenty-nine patients received 100–200 MBq 111In-labeled girentuximab. Whole-body and single photon emission computed tomography (SPECT) images were acquired after 4–7 d.
Injection with 111In-girentuximab and image acquisition after 4–7 d.
Outcome measurements and statistical analysis
Accuracy of 111In-girentuximab immunoSPECT.
Results and limitations
Distinct uptake of 111In-girentuximab was seen in 16 of 22 patients presenting with a renal mass. All renal masses proven to be ccRCC after resection (n = 15) were detected with 111In-girentuximab. Suspect lesions of six patients showed no uptake of 111In-girentuximab. In these patients, ccRCC was not found, nor progression occurred. Seven patients with a history of ccRCC and possible metastatic lesions on follow-up computed tomography scans were imaged with 111In-girentuximab. In four of these patients, the lesions showed preferential uptake of 111In-girentuximab and local or systemic treatment was initiated. In three other cases, no 111In-girentuximab targeting was seen. During follow-up of these three patients, one showed progression, for which systemic treatment was started. In the two other patients, no progression occurred, suggesting a benign nature.
111In-girentuximab immunoSPECT can be used to detect ccRCC lesions in patients with a primary renal mass and to clarify the nature of lesions suspect for metastases in patients with a history of ccRCC.
Recommend this article
Currently this article has a rating of 0. Please log in to recommend it.